Communicators

are winners!

More News

08.08.2023
RECCE: Positive Patients Update – Special Access Scheme
03.08.2023
Australian Patent Granted for RECCE® Anti-Infectives
28.07.2023
Recce Pharmaceuticals Ltd. - Bonus Canadian Scientific Research & Experimental Development Rebate Received
28.07.2023
Recce Pharmaceuticals Ltd. - Scientia Clinical Research Completes Cohort Dosing of Phase I/II UTI Rapid Infusion Clinical Trial
24.07.2023
Scientia Clinical Research Subjects Dosed in RECCE® 327 Rapid Infusion Phase I/II UTI Clinical Trial
20.07.2023
Clarification – 5-fold Increase to Concentration of RECCE® 327 in Urine and Plasma
19.07.2023
Phase I Clinical Trial Data Review Complete - RECCE® 327 as an Intravenous Infusion Formulation
12.07.2023
Recce A$801,604 R&D Rebate Advance Received
10.07.2023
First Cohort Dosed in RECCE® 327 Rapid Infusion - Phase I/II UTI Clinical Trial
29.06.2023
Recce Pharmaceuticals Receives Ethics Approval for RECCE® 327 Faster Infusion, Phase I/II Clinical Trial Expansion